Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931938 | 1.00 | KDM4E (0.44) | KDM4EKMT2ABACE1PI4KAPIK3CG | |
| SCHEMBL1712420 | 0.87 | KDM4E (0.52) | KDM4EKMT2ABACE1MAPK14NQO2 | |
| SCHEMBL4916971 | 0.82 | NQO1 (0.41) | KDM4EKMT2ATLR8NQO2MEN1 | |
| SCHEMBL11725621 | 0.81 | KDM4E (0.57) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL1138250 | 0.81 | MEN1 (0.59) | KDM4EKMT2AMAPK14NQO2MEN1 | |
| SCHEMBL1138314 | 0.81 | NQO2 (0.50) | KDM4EKMT2ABACE1TLR8NQO2 | |
| SCHEMBL4920558 | 0.81 | NQO2 (0.50) | KDM4EKMT2ABACE1TLR8NQO2 | |
| SCHEMBL4930422 | 0.81 | MEN1 (0.59) | KDM4EKMT2AMAPK14NQO2MEN1 | |
| SCHEMBL15870617 | 0.81 | KDM4E (0.46) | KDM4EKMT2AMAPK14NQO2MEN1 | |
| SCHEMBL804778 | 0.81 | KDM4E (0.46) | KDM4EKMT2AMAPK14NQO2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | claimed |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | claimed |
| EP-3344250-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | Rexahn Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | claimed |
| WO-2017040980-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3344250-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | Rexahn Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9969698-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-1819698-B1 | 1-[(6-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1819698-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | Rexahn Pharmaceuticals, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006054830-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | KDM4E 502/4885KMT2A 549/4885BACE1 4848/4885 |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | KDM4E 843/4885KMT2A 814/4885BACE1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.